Equities

Medivir AB

Medivir AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)3.28
  • Today's Change-0.09 / -2.67%
  • Shares traded153.19k
  • 1 Year change-46.62%
  • Beta0.1342
Data delayed at least 15 minutes, as of Sep 20 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of SEK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments170117221
Total Receivables, Net7.232.832.74
Total Inventory------
Prepaid expenses2.502.782.01
Other current assets, total------
Total current assets179123226
Property, plant & equipment, net121514
Goodwill, net------
Intangibles, net969696
Long term investments0----
Note receivable - long term----0
Other long term assets----0.00
Total assets288234336
LIABILITIES
Accounts payable163.7610
Accrued expenses258.1129
Notes payable/short-term debt000
Current portion long-term debt/capital leases2.272.111.05
Other current liabilities, total15141.15
Total current liabilities592842
Total long term debt111313
Total debt141614
Deferred income tax------
Minority interest------
Other liabilities, total0.00--0.00
Total liabilities704155
SHAREHOLDERS EQUITY
Common stock532828
Additional paid-in capital910805805
Retained earnings (accumulated deficit)(742)(637)(548)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(3.31)(3.24)(3.25)
Total equity218193281
Total liabilities & shareholders' equity288234336
Total common shares outstanding1046868
Treasury shares - common primary issue0.010.010.01
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.